Join
Live feed
·
PRReleasevia Quantisnow
Emergent BioSolutions Inc. logo

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

ByQuantisnow·Wall Street's wire, on your screen.
EBS· Emergent BioSolutions Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EBS (Emergent BioSolutions Inc.) and more on Quantisnow.